Liver cancer combo trial halted early: what we know
Disease control
Terminated
This study tested whether adding another drug (BMS-986253 or cabiralizumab) to the immunotherapy nivolumab could shrink tumors better than nivolumab alone in people with advanced liver cancer. The trial was stopped early and included only 13 participants, so results are limited. …
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated May 06, 2026 16:01 UTC